GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Total Inventories

Antares Pharma (Antares Pharma) Total Inventories : $11.6 Mil (As of Mar. 2022)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Total Inventories?

Antares Pharma's total inventories for the quarter that ended in Mar. 2022 was $11.6 Mil. Antares Pharma's average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was $11.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Antares Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $0.19.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Antares Pharma's Days Inventory for the three months ended in Mar. 2022 was 56.24.

Inventory Turnover measures how fast the company turns over its inventory within a year. Antares Pharma's Inventory Turnover for the quarter that ended in Mar. 2022 was 1.62.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Antares Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.28.


Antares Pharma Total Inventories Historical Data

The historical data trend for Antares Pharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Total Inventories Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.28 11.35 16.00 18.22 11.54

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.61 18.64 16.49 11.54 11.59

Antares Pharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Antares Pharma  (NAS:ATRS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Antares Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is

Net-Net Working Capital Per Share (Q: Mar. 2022 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(62.213+0.75 * 58.131+0.5 * 11.591-79.89
-0-0)/170.58
=0.19

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Antares Pharma's Days Inventory for the three months ended in Mar. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2022 )/Cost of Goods Sold (Q: Mar. 2022 )*Days in Period
=11.5675/18.767*365 / 4
=56.24

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Antares Pharma's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2022 ) / Average Total Inventories (Q: Mar. 2022 )
=18.767 / 11.5675
=1.62

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Antares Pharma's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=11.5675 / 41.557
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Antares Pharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447